NASDAQ:ERNA

Eterna Therapeutics (ERNA) Stock Price, News & Analysis

$2.22
+0.24 (+12.12%)
(As of 05/8/2024 ET)
Today's Range
$1.99
$2.30
50-Day Range
$1.56
$2.44
52-Week Range
$0.84
$3.16
Volume
24,595 shs
Average Volume
9,001 shs
Market Capitalization
$12.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ERNA stock logo

About Eterna Therapeutics Stock (NASDAQ:ERNA)

Eterna Therapeutics Inc. operates as a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. The company was formerly known as Brooklyn ImmunoTherapeutics, Inc. and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.

ERNA Stock Price History

ERNA Stock News Headlines

Tech GIANT’s Plans to Revolutionize Crypto…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Q4 2023 Cognition Therapeutics Inc Earnings Call
Tech GIANT’s Plans to Revolutionize Crypto…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Calidi Biotherapeutics Names Andrew Jackson CFO
See More Headlines
Receive ERNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eterna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
5/08/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ERNA
Employees
8
Year Founded
N/A

Profitability

Net Income
$-21,670,000.00
Pretax Margin
-31,869.12%

Debt

Sales & Book Value

Annual Sales
$68,000.00
Book Value
$0.41 per share

Miscellaneous

Free Float
3,493,000
Market Cap
$12.01 million
Optionable
No Data
Beta
4.31
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Ms. Sandra M. Gurrola (Age 57)
    Principal Financial & Accounting Officer and Senior VP of Finance
    Comp: $305.88k
  • Mr. Sanjeev Luther (Age 62)
    CEO, President & Director
  • Ms. Dorothy J. Clarke (Age 58)
    General Counsel & Director
  • Ms. Megan Yung
    Chief Strategy Officer

ERNA Stock Analysis - Frequently Asked Questions

How have ERNA shares performed in 2024?

Eterna Therapeutics' stock was trading at $1.7950 at the beginning of 2024. Since then, ERNA stock has increased by 23.7% and is now trading at $2.22.
View the best growth stocks for 2024 here
.

Are investors shorting Eterna Therapeutics?

Eterna Therapeutics saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 40,100 shares, a decrease of 5.4% from the March 31st total of 42,400 shares. Based on an average daily volume of 8,700 shares, the short-interest ratio is currently 4.6 days. Currently, 1.4% of the company's stock are sold short.
View Eterna Therapeutics' Short Interest
.

When is Eterna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ERNA earnings forecast
.

How were Eterna Therapeutics' earnings last quarter?

Eterna Therapeutics Inc. (NASDAQ:ERNA) posted its earnings results on Thursday, March, 14th. The company reported ($1.14) EPS for the quarter. The company had revenue of $0.02 million for the quarter.

Who are Eterna Therapeutics' major shareholders?

Eterna Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sippican Capital Advisors (1.35%) and Avidian Wealth Solutions LLC (0.27%). Insiders that own company stock include John D Halpern and Nicholas Jason Singer.
View institutional ownership trends
.

How do I buy shares of Eterna Therapeutics?

Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ERNA) was last updated on 5/9/2024 by MarketBeat.com Staff

From Our Partners